Bafna Pharmaceuticals Ltd. Hits Upper Circuit for the 2nd Straight Session on NSE, 28 October 2026

Pharma counters often get discussed as a pack, though the Bafna Pharmaceuticals upper circuit streak is a fact about a single stock: Bafna Pharmaceuticals Ltd. stood at Rs 451.6 on NSE on 28 October 2026, up 2% from the previous close of Rs 442.75, for the second session running at its limit. Nothing in the data lines it up against sector peers, so no such comparison is drawn.

The market cap is Rs 1063.83 crore, and the price was held at the band when this note was written.

Key Takeaways

• Bafna Pharmaceuticals Ltd. (BAFNAPH) hit the upper circuit on NSE at Rs 451.6 on 28 October 2026.
• The session move was +2% against a previous close of Rs 442.75.
• Market capitalisation stood at Rs 1063.83 crore with a PE ratio of 136.6.
• This is the 2nd straight session at the upper circuit, with the run starting on 27 October 2026.
• A price band is an exchange trading rule, not a view on the company or a recommendation.

Key Market Data

Metric	Value
Stock	Bafna Pharmaceuticals Ltd.
Current Price / LTP	Rs 451.6
Day Move	2%
Previous Close	Rs 442.75
Day Open	Rs 0
Day High	Rs 451.6
Day Low	Rs 451.6
Upper Circuit Price	Rs 451.6
Upper Circuit Limit	Rs 451.6
Market Cap	Rs 1063.83 crore
Selected Exchange	NSE
PE Ratio	136.6

All figures above are as of 28 October 2026, sourced from Univest market data for the NSE listing. Only fields present in the source for this session are shown.

Price Action and Trading Activity

Bafna Pharmaceuticals Ltd. traded on NSE with its session high and low both at Rs 451.6, so the day shows no range at all and the price sat on the band price throughout. Set beside the prior close of Rs 442.75, that is a rise of Rs 8.85, which works out to 2%.

The band on this stock is a narrow one, which is why a 2% move already reaches the ceiling. Every number here is an NSE number. A sector peer on another exchange, or one with a wider band, could show a very different percentage at its own limit, so a like-for-like comparison would need data this note does not attempt to supply.

The Bafna Pharmaceuticals Upper Circuit Streak So Far

This is session 2 of an unbroken run for Bafna Pharmaceuticals Ltd. The streak began on 27 October 2026, from a base price of Rs 440.9. Across the run the stock has moved 2.43% in total.

A repeated upper circuit matters more than a single one. It says the order book has stayed one-sided across multiple sessions rather than reacting to a single day of news, and for anyone holding the stock it means the price on screen has been hard to trade at for several days running.

This page is the running record for the streak and is updated each session rather than being replaced by a fresh article. That keeps one address for the event instead of splitting the same story across competing pages.

Why Bafna Pharmaceuticals Ltd. Hit Upper Circuit

Buying interest took Bafna Pharmaceuticals Ltd. to the edge of its exchange band, and the upper circuit then held the price at Rs 451.6. Company filings and outside news provided no verified reason for the day, so the pharmaceutical sector is not given credit for the move and price action with sentiment is all that can be read.

Earnings, corporate actions and rumours are also left out as explanations, since none of them is confirmed. If a confirmed announcement comes, a separate update would carry it.

Rs 451.6 was the upper circuit level in the session.

What the Bafna Pharmaceuticals Upper Circuit Means

An upper circuit in one pharma stock does not describe the whole group. For Bafna Pharmaceuticals Ltd. the price has reached the ceiling set for the session, Rs 451.6 on 28 October 2026, and the finding applies to this one name only.

Bands exist to slow sharp swings and keep trading orderly. They describe what the sessions did and offer no forecast of returns, and they reveal nothing about how other drug makers traded on the day, so the reading stays with this one stock.

Bafna Pharmaceuticals Ltd. Fundamentals and Valuation

Reported data supplies more context than the price move. Bafna Pharmaceuticals Ltd. carries a market cap of Rs 1063.83 crore, book value of Rs 40.68, EPS of 3.29, a PE ratio of 136.6 and a PB ratio of 11.06. None of it is a buy, sell or hold view.

Against that, book value of Rs 40.68 a share lies far below the quote, and the PB ratio of 11.06 is simply the size of that gap. The PE ratio of 136.6 comes from EPS of 3.29, so the price is a very large multiple of earnings per share. A premium of this size might mirror hopes for growth, the quality of assets or thin trading in a smaller counter, and the ratios on their own do not decide between those. The company is in the healthcare sector, in pharmaceuticals and drugs.

Two sessions at the ceiling attract attention, yet valuation, returns and the sector backdrop each need a review of their own.

Peer and Sector Context

Bafna Pharmaceuticals Ltd. belongs to the Pharmaceuticals & Drugs industry within the Healthcare sector. The peer table below uses available companies from the same sector or industry to give broader valuation context.

Peer Company	Market Cap	PE	PB	ROE
Advanced Enzyme Technologies Ltd.	Rs 2905.78 crore	17.52	1.75	11.43%
Hikal Ltd.	Rs 2494.37 crore	-	2.09	-3.97%
Fredun Pharmaceuticals Ltd.	Rs 2490.64 crore	56.84	8.17	16.09%
Dishman Carbogen Amcis Ltd.	Rs 2314.9 crore	143.25	0.35	1.56%
Beta Drugs Ltd.	Rs 2151.07 crore	41.43	4.91	18.78%

A dash in the PE column means no PE ratio was carried for that company in the source data, which happens when reported earnings are negative or have not been refreshed. Those companies are left out of the average below rather than counted as zero.

Bafna Pharmaceuticals Ltd.'s PE ratio was 136.6, compared with an available peer PE average of 64.76, calculated from the 4 peer companies that had a PE on record. This comparison is a valuation reference point, not a recommendation.

Technical Snapshot

The technical snapshot adds context: RSI was 67.25, the 50-day moving average was 409.26 and the 200-day moving average was 267.75.

What Readers Should Know

What is confirmed is narrow: on 28 October 2026 Bafna Pharmaceuticals Ltd. sat at Rs 451.6, the NSE ceiling, with a 2% gain and a second session at that level. Tying it to the wider drug sector would take evidence that is not part of this note.

At the ceiling, orders queue on the buy side while sellers hold back, so the quoted price is not always one at which a trade completes. No official catalyst has been identified for the move.

Treat this as a market update only. Holding at the ceiling does not stand in for a separate look at the business, its valuation, liquidity, risk and any confirmed company disclosures.

Frequently Asked Questions

Why did Bafna Pharmaceuticals Ltd. hit upper circuit on 28 October 2026?

The stock reached its upper price band after buying interest during the session. No official company announcement or verified external catalyst was confirmed at the time of writing.

How many sessions has Bafna Pharmaceuticals Ltd. hit upper circuit in a row?

This is session 2 of the current run, which began on 27 October 2026. This page is updated each session rather than replaced with a new article.

What was BAFNAPH share price on 28 October 2026?

The last traded price used in this article was Rs 451.6 on NSE. That price matched the upper circuit price captured for the event.

What was the upper circuit price for BAFNAPH?

The upper circuit price was Rs 451.6. The stated exchange upper circuit limit was Rs 451.6. The event numbers in this article are aligned to NSE.

What is Bafna Pharmaceuticals Ltd.'s market cap and PE ratio?

Bafna Pharmaceuticals Ltd.'s market cap was Rs 1063.83 crore. PE ratio was 136.6.

Which exchange and data source were used?

The selected exchange was NSE. The article uses Univest market data available at the time of generation, captured on 28 October 2026.

Does hitting an upper circuit mean Bafna Pharmaceuticals Ltd. is a buy or a sell?

No. A circuit is an exchange price-band rule that caps how far a stock can move in a single session. It carries no view on valuation or business quality and is not a recommendation. Any decision should rest on fundamentals, valuation, liquidity and your own risk tolerance.

Can you buy or sell Bafna Pharmaceuticals Ltd. shares when the stock is at the upper circuit?

It is usually difficult. At the upper circuit, buy orders queue up while sellers step back, so there may be no counterparty at the quoted price. Orders can stay unfilled until the band opens up or sellers return.

What happens the next trading session after an upper circuit?

There is no fixed outcome. The band resets each session, so the stock can open freely, hit the same band again, or reverse. The exchange can also revise the applicable band width. The useful signals to watch are whether the company files any disclosure explaining the move.

What is the upper circuit limit set at for Indian stocks?

Exchange price bands are commonly set at 2%, 5%, 10% or 20% depending on the security, and the applicable band can be revised by the exchange. For Bafna Pharmaceuticals Ltd. the stated limit was Rs 451.6. For this session, Bafna Pharmaceuticals Ltd. moved 2%.